Targeted Strategies for Today's Evolving Markets

MissionIR Blog

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

  • XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule”
  • The program, which started in early 2021, is slated for completion in late Q3 2021
  • The first initial production batches were completed successfully, marking a significant milestone for the program
  • Mescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation work

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) recently announced that its Good Manufacturing Practices (“GMP”) mescaline synthesis program in North America is “on schedule” for completion in late Q3 2021 ( So far, the company has completed the production of the initial batches and streamlined operations in readiness for scaling Its current focus is on the growth of production capability and the development of analytical methods of validation. 

“With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto’s psychedelic medicine program is progressing on schedule. As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation,” said Hugh Rogers, XPhyto’s CEO ( 

Back in early 2021, XPhyto announced its move to focus its resources and expertise on using active pharmaceutical ingredients for neurological application. These included psychedelic compounds, such as mescaline and psilocybin, and cannabinoids. The two psychedelic compounds form critical components in the company’s psychedelic medicine program, while working towards providing a foundation for its drug formulation and clinical validation work.

This Vancouver-based life sciences technology accelerator is known for constantly pushing the envelope in bioscience research, focusing on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. So far, it has made considerable strides in precision transdermal and oral dissolvable drug formulations, the rapid, low-cost infectious disease and oral health screening tests and, most importantly, the standardization of emerging active pharmaceutical ingredients for neurological applications ( 

XPhyto is confident that mescaline can become the next frontier in the current ongoing psychedelics renaissance. It is a product that presents the opportunity to innovate and improve on existing methods of mental health therapy, having already proven effective in the treatment of mental health-related medical conditions that include, but are not limited to anxiety, depression, addiction and trauma-related stress disorder.

Mescaline is a naturally occurring psychedelic compound, typically found in specific cacti. In a recent publication by ACS Pharmacology and Translational Science, it was noted that the naturalistic use of mescaline is linked to psychiatric improvements and lasting positive life changes. It was further pointed out that its use among individuals with alcohol and drug use disorders (“AUD” and “DUD”), along with post-traumatic stress disorder (“PTSD”), all reported significant improvement following mescaline use and accompanying treatment ( 

With the current strides that XPhyto is making with its mescaline program, it is slowly laying the foundation for mental health therapy and the treatment of various mental health-related conditions. Additionally, it further plays a more significant role in sensitizing society on the usefulness and potential of psychedelic compounds and cannabinoids. XPhyto is also serving as proof of the financial viability of pharmaceutical-grade psychedelics and their use in treating psychological illnesses.

“We see a significant market opportunity in the production of pharmaceutical-grade psychedelics followed by the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use,” Hugh mentioned.

Currently, XPhyto has development operations in North America and Europe and an operational focus in Germany. As it focuses on scaling up its production capability, the company is also working on developing standard operating procedures (“SOP”) for GMP certification of its synthesis process.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in XPhyto Therapeutics Corp. XPHYF. Bookmark the permalink.

Comments are closed.